Related by context. All words. (Click for frequent words.) 70 MEND CABG II 70 Phase IIb III 70 MEND CABG 70 pivotal bioequivalence 69 RSD# oral 69 multicenter Phase II 69 phase IIa clinical 68 riociguat 68 thorough QT 68 phase IIa 68 teriflunomide 68 PRIMO CABG2 68 BRIM3 68 STRIDE PD 68 CARE HF 68 NP2 Enkephalin 68 phase IIb study 67 phase IIb clinical 67 AVADO 67 dose escalation phase 67 Phase IIIb clinical 67 prospectively defined 67 randomized Phase IIb 67 elotuzumab 67 confirmatory clinical 67 midstage clinical 67 randomized controlled multicenter 67 PFO migraine 67 budesonide foam 66 landmark ATHENA 66 EDEMA4 66 dose escalation Phase 66 dose escalation clinical 66 MAGE A3 ASCI 66 subcutaneous PRO 66 Phase Ib II 66 EDEMA3 66 tolevamer 66 PEARL SC 66 MERLIN TIMI 66 active comparator 66 ToGA 66 ExTRACT TIMI 66 placebo controlled clinical 66 multicenter randomized placebo controlled 66 Phase Ib clinical 66 CUSTOM III 66 ABSORB trial 66 IMA# 66 APEX AMI 66 galiximab 66 Phase Ib study 65 oral ridaforolimus 65 oral rivaroxaban 65 sNDA submission 65 alvespimycin 65 oral methylnaltrexone 65 ENDEAVOR III 65 EchoCRT 65 oxymorphone ER 65 recurrent malignant glioma 65 Phase #b/#a 65 OvaRex ® MAb 65 APEX AMI trial 65 EDEMA3 trial 65 Ereska 65 relapsed MCL 65 ROCKET AF 65 CHAMPION PCI 65 pharmacokinetic PK study 65 TEMSO 65 CHAMPION PLATFORM 65 Phase #/#a 65 CA9 SCAN 65 placebo controlled Phase III 65 ANCHOR trial 65 NATRECOR ® 65 efficacy endpoint 65 APEX PD 65 unblinding 65 Phase III VISTA 65 phase IIb 65 EMPOWER ™ 64 Zemplar Capsules 64 preclinical pharmacokinetic 64 rALLy trial 64 evaluating Actimmune 64 NSABP C 64 phase Ib 64 elacytarabine 64 NATRECOR R 64 GSK# [002] 64 ADVANCE PD 64 viral kinetic 64 dexanabinol 64 AVERROES 64 dose cohort 64 Proellex TM 64 rALLy 64 NO# [002] 64 metastatic HRPC 64 noninferiority 64 ELACYT 64 Prostate AdenoCarcinoma Treatment 64 EmbraceAC 64 RE LY ® 64 Phase 1a clinical 64 placebo controlled Phase 64 IMPACT DCM 64 recombinant PSMA vaccine 64 TAXUS IV 64 Phase 2b kidney transplant 64 multicenter trials 64 XL# SAR# 64 trastuzumab emtansine T DM1 64 cannabinor 64 prospective multicenter randomized 64 RIO Lipids 64 evaluating mipomersen 64 ENRICH trial 64 relapsing remitting MS RRMS 64 lomitapide 64 pharmacokinetic PK 64 TASKi3 64 cangrelor 64 VADT 64 Phase 2b study 64 nonrandomized 64 Zevalin consolidation 64 confirmatory Phase III 64 tramiprosate Alzhemed TM 64 pharmacodynamic effects 64 registrational 64 TASKi2 64 EXPLORE Xa 64 vidofludimus 64 enzastaurin 64 BRIM2 64 bicifadine 64 secondary efficacy endpoints 63 HCV SPRINT 63 ruxolitinib 63 Ophena TM 63 Corlux 63 multicenter Phase III 63 PARTNER Trial 63 recurrent glioblastoma multiforme 63 Prestara 63 Phase III ADT 63 SIMPADICO 63 Teriflunomide 63 GOUT 63 trastuzumab DM1 T DM1 63 Randomized controlled 63 placebo controlled dose escalation 63 Urocortin 2 63 CIMZIA TM certolizumab pegol 63 refractory CLL 63 severe hypercholesterolemia 63 ACCEDE 63 opioid induced bowel dysfunction 63 PCI ExTRACT TIMI 63 HF ACTION 63 huC# DM4 63 fidaxomicin Phase 3 63 randomized blinded 63 DU #b 63 NEUVENGE 63 Balaglitazone 63 phase Ib clinical 63 subcutaneous methylnaltrexone 63 TBC# 63 phase IIb III 63 Phase #b/#a clinical 63 multicentre randomized 63 MIST II 63 ILLUMINATE 63 Hepatocellular Carcinoma HCC 63 Phase Ib IIa 63 double blinded placebo 63 treatment naive genotype 63 QTc prolongation 63 including eniluracil ADH 63 ORAL Sync 63 pain palliation 63 tecarfarin 63 ongoing Phase 1b 63 antiangiogenic therapy 63 ALN VSP Phase 63 deforolimus 63 Anturol TM 63 ZYBRESTAT fosbretabulin 63 CLORETAZINE TM VNP#M 63 ACTEMRA TM 63 HCV RESPOND 2 63 fostamatinib 63 multicenter randomized controlled 63 rALLy clinical trial 63 modified REGENESIS Phase IIb 63 EMPHASIS HF trial 63 relapsed MM 63 Carotid Revascularization Endarterectomy vs. 63 GetGoal Phase III 63 canagliflozin 63 eritoran 63 ponatinib 63 Phase IIa trial 63 LUX Lung 63 Phase IIB 63 forodesine 63 ENDEAVOR IV 63 Phase IIIb study 63 randomized multicenter trial 63 Lu AA# 62 COMFORT II 62 phase IIb trial 62 mg/m2 cohort 62 PDE# inhibitors 62 REVIVE TA 62 multicenter Phase 62 elective PCI 62 CBLC# 62 Phase 1b trial 62 velafermin 62 placebo controlled multicenter 62 placebo controlled randomized 62 Telintra 62 confirmatory pivotal 62 diabetic neuropathic pain 62 MADIT II 62 MKC# MT 62 PRECISE Trial 62 LymphoStat B belimumab 62 multicenter placebo controlled 62 evaluating tivozanib 62 ONCONASE R 62 prospective randomized controlled 62 adjuvant colon cancer 62 Phase IIb trials 62 CURE AF 62 ASTEROID 62 ADAGIO study 62 Plicera 62 JAK inhibitor 62 Phase IIIb 62 Subgroup analysis 62 Genz # 62 solanezumab 62 catheter occlusion 62 cediranib 62 budesonide MMX Phase III 62 fusion enhancers 62 GENASIS trial 62 nalbuphine ER 62 Phase 1b clinical trials 62 Phase 1b clinical 62 Phase #b/#a trial 62 MGd 62 ABSORB clinical 62 trials RCTs 62 trastuzumab DM1 62 Phase 1a 62 intravenous methylnaltrexone 62 Aplidin 62 SPIRIT FIRST 62 cilengitide 62 IMPACT IMmunotherapy 62 Phase IIa clinical 62 dirucotide MBP# 62 axitinib 62 Phase IIb clinical trials 62 randomized Phase III 62 CALGB # [002] 62 NEO3 62 PREVENT IV 62 Neuvenge 62 pramlintide metreleptin combination 62 prospectively stratified 62 SUCCEED trial 62 desvenlafaxine succinate 62 cortical stimulation 62 IND submission 62 CIMZIA ™ 62 RE LY 62 SYMMETRY trial 62 aerosolized KL4 surfactant 62 Androxal TM 62 GALNS 62 pertuzumab 62 pharmacokinetic equivalence 62 NSABP 62 double blinded randomized 62 randomized discontinuation trial 62 symptomatic VTE 62 DAPT 62 urinary N telopeptide 62 TAXUS VI 62 GEM OS1 62 placebo controlled studies 62 ALSYMPCA 62 bardoxolone 62 Elocalcitol 62 RECORD1 62 neratinib 62 edifoligide E2F Decoy 62 Dextofisopam 62 BARI 2D 62 motesanib 62 Val HeFT 62 initiate Phase 1b 62 CINQUIL 62 oral deforolimus 62 Phase III confirmatory 62 REVIVE Diabetes 62 virus HCV protease inhibitor 62 GENASIS 62 GLP toxicology studies 62 Phase 2a trial 62 AGILECT R 62 HGS# 62 Phase 2a clinical 62 tanespimycin 62 cariprazine 61 #mg dose [002] 61 Kynapid 61 ACCORD Lipid 61 AGHD 61 ATL# [001] 61 dacetuzumab 61 ZOLINZA 61 compound INCB# 61 prospective multicentre 61 evaluating Prochymal 61 brivaracetam 61 phase IIIb 61 PROSTVAC TM 61 methylnaltrexone 61 pharmacodynamics PD 61 Maximum Tolerated Dose MTD 61 MGN# 61 maximally tolerated dose 61 Aflibercept 61 midstage trials 61 Cimzia TM 61 phase 2a 61 retinal vein occlusion induced 61 CLARITY study 61 IMPACT DCM clinical 61 assessing T DM1 61 Trofex 61 azilsartan medoxomil 61 pharmacokinetics PK 61 CRMD# 61 PRECISE trial 61 nonclinical studies 61 clinical pharmacology studies 61 lumiliximab 61 morphometric vertebral fractures 61 acyclovir Lauriad ® 61 systemic anaplastic large 61 biliary tract cancer 61 refractory metastatic colorectal cancer 61 TRA 2P 61 Vernakalant 61 Augment Injectable 61 Phase IIb clinical 61 RhuDex TM 61 preclinical efficacy 61 acute mania 61 intravenous RSD# 61 Phase III randomized controlled 61 randomized Phase 2b 61 opioid naive 61 stratifying patients 61 ASCEND HF 61 recurrent glioblastoma 61 tesmilifene 61 bovine thrombin 61 clazosentan 61 lintuzumab SGN 61 Pivotal Phase III 61 Prodarsan ® 61 prospective randomized multicenter 61 metaglidasen 61 PSMA ADC 61 TG MV 61 Phenoptin 61 Phase IIa trials 61 genotypic resistance 61 ECASS 61 ACAPODENE 61 initiate multicenter 61 endoscopic remission 61 rindopepimut 61 Amoxicillin PULSYS Phase III 61 TACI Ig 61 BrachySil TM 61 Perceiva 61 eprotirome 61 MYTHOS trial 61 EOquin TM 61 intravenous cyclophosphamide 61 placebo controlled clinical trials 61 oral picoplatin 61 edifoligide 61 EOquin TM phase 61 chronic thromboembolic pulmonary 61 MEK inhibitor RDEA# 61 HuMax EGFr 61 budesonide MMX 61 DASISION 61 HIV coinfected 61 Primary endpoints 61 Allovectin 7 61 T Pred 61 Diamyd ® 61 relapsed refractory multiple myeloma 61 YONDELIS 61 canakinumab 61 UPLYSO 61 angiographic outcomes 61 dosing cohort 61 gadobutrol 61 postapproval 61 antiretroviral naïve 61 liposomal amphotericin B 61 GRN# 61 CYT# potent vascular disrupting 61 prospective multicenter 61 BLA filing 61 multicenter clinical 61 LymphoStat B Phase 61 hemostatic efficacy 61 TAXUS V 61 RRMS patients 61 LymphoStat B TM 61 Vectibix panitumumab 61 regorafenib 61 clevidipine 61 ospemifene 61 neurologic progression 61 R#/MEM # 61 prospective multicenter study 61 schizophrenia CIAS 61 PI3K/Akt pathway inhibitor 61 GSK# [001] 61 EndoTAG TM -1 61 ONTARGET 61 REMINYL ® 61 bioequivalency 61 Medidur TM FA 61 oral prodrug 61 alvimopan 61 cilostazol 61 ZACTIMA 61 EMPOWER TM 61 CTAP# Capsules 61 Targretin capsules 61 EndoTAGTM 1 61 vasogenic edema 61 octreotide implant 61 oral FTY# 61 GAMMAGARD 61 pexelizumab 61 KRAS mutations occur 61 Tasigna prolongs 61 Thorough QT Study 61 metreleptin 60 INVEGA ® 60 Aptivus ® 60 initiate Phase IIa 60 tarenflurbil 60 midstage studies 60 ACTIVE W 60 SUTENT ® 60 adecatumumab 60 Bayer HealthCare Onyx Pharmaceuticals 60 fluvastatin 60 eculizumab therapy 60 ACCLAIM COPD 60 iclaprim 60 HGS ETR2 60 phase III ACCLAIM 60 icatibant 60 dose escalation trial 60 SYNTAX trial 60 Prosaptide 60 registrational clinical 60 multicenter randomized clinical 60 RoACTEMRA 60 baminercept 60 Fibrillex TM 60 initiate Phase 2b 60 randomized controlled clinical 60 Bicifadine 60 sitaxsentan 60 pharmacokinetic characteristics 60 AIR CF2 60 Novolimus 60 RezularTM 60 evaluating REVLIMID 60 vismodegib 60 HCV NS5B polymerase 60 Arranon 60 BCIRG 60 NOX E# 60 Phase IIa clinical trials 60 initiated Phase Ib 60 dose titration 60 IIa trial 60 GLYX 60 Diamyd r vaccine 60 HORIZONS AMI trial 60 DEB# 60 ORBIT II 60 PrevOnco 60 AIM HIGH 60 BR.# 60 NV1FGF 60 Lofexidine 60 MyVax personalized immunotherapy 60 crizotinib PF # 60 Randomized Phase II 60 fosbretabulin 60 dosage regimens 60 multicenter prospective 60 Phase lll 60 PANVAC VF 60 dose cohorts 60 carotid endarterectomy CEA 60 APF# Phase 60 Cariprazine 60 prostate cancer CaP 60 HER2 expression 60 rolofylline 60 LHRH receptor positive 60 lupus nephritis 60 Canvaxin 60 LY# [003] 60 prucalopride 60 prospective randomized placebo 60 randomized multicentre 60 Phase 2a 60 generation antisense inhibitor 60 VITAL Trial 60 VA# [002] 60 BETAS 60 diarrhea predominant irritable 60 RIO Diabetes 60 Secondary efficacy endpoints 60 recurrent metastatic ovarian cancer 60 unique alkylating agent 60 dirucotide 60 Azedra 60 deferiprone 60 XIENCE V demonstrated 60 Fx #A 60 Bezielle 60 haematologic 60 hypercholesterolemic patients 60 subgroup analyzes 60 clinical endpoints 60 Phase 2b trial 60 Dacogen injection 60 ASSERT trial 60 meta analysis pooling 60 serum phosphorous 60 GEM OS2 60 novel VDA molecule 60 Edge STudy 60 recurrent GBM 60 renal denervation 60 opioid naïve 60 Onrigin 60 Certican 60 randomized multicenter 60 AVN# Phase 60 novel therapeutic antibodies 60 CLIRS trial 60 liver resection 60 LCP AtorFen 60 placebo controlled trials 60 Initiated Phase 60 MVA MUC1 IL2 60 BENICAR HCT 60 Deforolimus 60 Ceplene/IL-2 60 Xelox 60 Aurexis 60 eprodisate Fibrillex TM 60 Multicenter Automatic Defibrillator Implantation 60 unblind 60 SORT OUT III 60 radiographic outcomes 60 Thorough QT 60 XmAb# 60 prospective nonrandomized 60 QTinno TM 60 PROSTVAC ® 60 ARIKACE ™ 60 GLP1 agonist 60 ARCOXIA 60 number NCT# ClinicalTrials.gov 60 Committee IDMC 60 Cloretazine 60 zanolimumab 60 dextofisopam 60 telaprevir dosing 60 acyclovir Lauriad R 60 solid tumors ZYBRESTAT 60 blinded randomized 60 olaparib 60 Sibutramine Cardiovascular Outcomes 60 XIENCE V PROMUS Stent 60 PROVENGE sipuleucel T 60 Entereg R 60 PRE SURGE 60 TMC# C# 60 randomized multicenter Phase III 60 SILENOR 60 smoldering multiple myeloma 60 pomalidomide 60 Archexin 60 null responder HCV 60 Ocrelizumab 60 Allovectin 7 ® 60 TELCYTA 60 PLCO trial 60 PROMUS Element Stent 60 MoxDuo ® IR 60 SPARLON 60 Traficet EN 60 afatinib 60 ThermoDox ® clinical 60 Viramidine 60 Gattex 60 pharmacokinetic studies 60 Intervention Effectiveness 60 deCODE AF TM 60 randomized controlled Phase 60 CANCIDAS 60 Zenvia ™ 60 AA Amyloidosis 60 controlled multicenter Phase 60 initiate Phase IIb 60 glycated hemoglobin levels 60 INS# [001] 60 NSABP B 60 randomized controlled clinical trials 60 GATTEX ® 60 goserelin 60 APPRAISE 60 MYDICAR 60 tocilizumab 60 phase III isavuconazole 60 ViaDerm hPTH #-# 60 comparator arm 60 ganetespib 60 Tarceva TM 59 pediatric malignancies 59 naïve HCV 59 ancrod 59 Dose escalation 59 mITT population 59 florbetaben 59 Afatinib 59 pharmacodynamic properties 59 orBec 59 Kahalalide F 59 percutaneous cryoablation 59 prospective observational studies 59 FOLFOX6 chemotherapy regimen 59 Poly ICLC 59 remission CR 59 INTERCEPT platelets 59 COU AA 59 PERSEUS 59 Safinamide 59 GENZ # 59 tramiprosate ALZHEMED TM 59 vernakalant hydrochloride 59 registrational Phase 59 trial evaluating PRX# 59 PRESEPT study 59 Zenvia TM 59 GRNVAC1 59 SAR# [004] 59 DIRECT Trial 59 postoperative chemotherapy 59 secondary efficacy endpoint 59 cardiac repolarization 59 Asentar 59 HBV infections 59 somatostatin analog 59 Phase III multicenter 59 Oglemilast 59 Phase III HEAT 59 Phase Ia 59 IRX 2 59 huN# DM1 59 ruboxistaurin 59 AMPAKINE CX# 59 Cinquil 59 darapladib 59 OPT CHF 59 Xcytrin R 59 torcetrapib atorvastatin 59 receptor tyrosine kinase inhibitor 59 registrational trial 59 Femara letrozole 59 Rezular 59 heavily pretreated 59 RhuDex ® 59 tremelimumab 59 Phase 2a clinical trials 59 Tarvacin Anti Cancer 59 MIRCERA 59 PD LID 59 CRp 59 Solorel 59 evaluating T DM1 59 prospectively randomized 59 TRIST 59 Ceflatonin 59 intermittent dosing 59 dose proportionality 59 EXJADE 59 relapsed ALL 59 abacavir lamivudine 59 DPX Survivac 59 rFVIIa 59 symptomatic paroxysmal AF 59 muraglitazar 59 dalbavancin 59 eosinophilic asthma 59 pradefovir 59 thromboprophylaxis 59 chronic myocardial ischemia 59 hereditary deficiency 59 rhThrombin 59 AFRS TM 59 Phase III placebo controlled 59 figitumumab 59 Evoltra ® 59 iloprost 59 nab paclitaxel 59 PreCISe 59 Randomized Phase 59 PHX# 59 SPIRIT IV 59 Testosterone MDTS ® 59 Stimuvax R 59 ACCORD COPD 59 coinfected patients 59 ENGAGE AF TIMI 59 miconazole Lauriad ® 59 dosing cohorts 59 maximal doses 59 PROCHYMAL 59 QLT Plug Delivery 59 Valtropin 59 includes TOLAMBA TM 59 oral mTOR inhibitor 59 bepotastine besilate nasal spray 59 PF # [002] 59 AVOREN 59 Daclizumab 59 urocortin 2 59 Sudhir Agrawal D.Phil 59 PEG PAL 59 hepatitis B vaccine Heplisav 59 inhaled iloprost 59 PCA3 assay 59 PMA submission 59 zotarolimus 59 INCB# [001] 59 Betaferon ® 59 TransVax 59 Phase Ib 59 multicentre study 59 Phase Ib clinical trials 59 Pirfenidone 59 BLA submission 59 unstable angina UA 59 APTIMA HPV assay 59 anti arrhythmic drug 59 metastatic castration resistant 59 Cleviprex TM clevidipine 59 MitraClip device 59 ofatumumab HuMax CD# 59 ocrelizumab 59 intravenous belinostat 59 Telatinib 59 cytokine refractory 59 SEPET TM 59 HeFH 59 vemurafenib 59 Empatic ™ 59 mapatumumab 59 viral kinetics 59 visilizumab 59 Ophena 59 tramiprosate 59 cobiprostone 59 Tovaxin Phase IIb 59 Phase 2b clinical trials 59 Trandolapril 59 randomized controlled trials RCTs 59 INSPIRE Trial Phase III 59 Phase #/#a clinical 59 Virulizin ® 59 ThGRF 59 refractory AML 59 definite stent thrombosis 59 OVATURE 59 myopic CNV 59 ragweed allergy immunotherapeutic 59 ConclusionThis 59 CALGB 59 iniparib 59 COSIRA trial 59 eTag assays 59 elagolix 59 antibody MAb 59 generation purine nucleoside 59 pharmacogenomic translational research 59 Urocidin 59 glufosfamide 59 HBeAg negative patients 59 Canvaxin TM 59 LUMINATE 59 SinuNase ™ 59 noninvasive outpatient 59 heterozygous FH 59 HYVET 59 ATACAND 59 IMPROVE IT 59 micafungin 59 Curaxin CBLC# 59 multicenter phase 59 BEMA TM LA 59 Provacel 59 E2F Decoy 59 Serdolect 59 orally administered inhibitor 59 lenalidomide Revlimid 59 Coronary angiography 59 SinuNase TM 59 eliglustat tartrate 59 Insulin PH# 59 PLX STROKE targeting 59 lorvotuzumab mertansine 59 underwent coronary angiography 59 EURIDIS 59 invasive candidiasis 59 genomic biomarker 59 DDP# 59 Aryplase 59 PEGINTRON TM 59 Exherin TM 59 preclinically 59 heFH 59 psoriatic arthritis PsA 59 UVIDEM 59 PROTECT AF 59 albiglutide 59 kidney urologic 59 pCR 59 Radical prostatectomy 59 DCCR 59 OvaRex 59 adecatumumab MT# 59 Cloretazine ® 59 antiarrhythmic 59 REG1 Anticoagulation System 59 Vicriviroc 59 Contrave# 59 factor Xa inhibitor 59 CRLX# 59 multicenter multinational 59 orally inhaled migraine 59 cerebrovascular events 59 Certolizumab pegol 59 multicentric 59 SNT-MC#/idebenone 59 humanised monoclonal antibody 59 ORMD 59 recurrent herpes labialis 59 beta 1a 59 atrial arrhythmias 59 cetuximab Erbitux 59 ADMIRE HF 59 Edwards SAPIEN valve 59 liposomal formulation 59 Dyloject TM 59 blinded randomized placebo controlled 59 paclitaxel eluting stents 59 Subgroup analyzes 59 Zybrestat 59 zileuton IV 59 bevirimat Study 59 prognostic indicators 59 intravesical therapy 59 visceral metastases 59 SNT MC# 59 senicapoc 59 omecamtiv mecarbil 59 multidose 59 PRESEPT 59 NovoTTF 59 ICON7 59 AKT inhibitor 59 certolizumab 59 Tekamlo 59 FOLOTYN ® 59 apremilast 59 basal bolus regimen 59 TRITON TIMI 59 #mg ATC 59 masked placebo controlled 58 Fibrillex 58 patients undergoing CABG 58 plasma pharmacokinetics 58 inhaled formulation 58 hypoxia activated prodrug 58 Pagoclone 58 TLK# 58 phase III SIMPADICO 58 Golimumab 58 safety tolerability pharmacokinetic 58 Benlysta belimumab 58 Prodarsan R 58 mRCC 58 Alzhemed TM 58 ABCSG 58 inhaled AAT 58 HDL Selective Delipidation 58 Phase #/#a trial 58 Pimavanserin 58 Solazed 58 EVEREST II 58 postoperative atrial fibrillation 58 Capesaris 58 cystinosis patients 58 PROTECT II 58 Renal Cell Carcinoma RCC 58 MYDICAR ® 58 EndoTAG TM 58 ER CHOP 58 revascularizations 58 Study GL# 58 pregabalin Lyrica 58 Tectin TM 58 aclidinium bromide 58 RSR# 58 Enzastaurin 58 CAPACITY trials 58 adult chronic ITP 58 dose dose escalation 58 NLX P# 58 pharmacodynamic PD 58 dose intramuscular 58 ENDEAVOR IV clinical 58 painful diabetic neuropathy 58 pazopanib 58 ProSavin 58 CytoFabTM 58 CURRENT OASIS 7 58 Rhucin R 58 hypersensitivity allergic reactions 58 H. pylori eradication 58 ORAL Solo 58 Trastuzumab DM1 58 randomized crossover 58 refractory angina 58 BrachySil 58 OvaRex MAb 58 mTOR inhibition 58 Advaxis Phase 58 ritonavir boosted 58 TOLAMBA 58 APTIVUS 58 microbiologically evaluable 58 metastatic malignant melanoma 58 fallopian tube cancers 58 granted Ortec 58 lenalidomide dexamethasone 58 ADVEXIN therapy 58 Triapine R 58 CAMMS# 58 Phase 2b clinical 58 EGS# 58 FOSRENOL ® 58 OBPM 58 pharmacokinetic PK profile 58 tolvaptan 58 Phase IIIB IV 58 Wyeth Progenics 58 DAS# CRP